EGRX LOW RISK AND HIGHT REWARD

EGRX broke another key resistance zone, it is in a nice zone to a long entry.

And today:
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product (“RTU bivalirudin”) has been accepted for filing by the U.S. Food and Drug Administration (FDA).

finance.yahoo.com/news/eagle-pharmaceuticals-rtu-bivalirudin-nda-110000493.html